Sobi publishes Annual Report

Sobi publishes Annual Report 
STOCKHOLM, SWEDEN -- (Marketwired) -- 04/05/13 --  
Swedish Orphan Biovitrum AB (Sobi) today published its Annual
Report for 2012,
themed "Building value for patients, partners and
shareholders", on the company's website, 
The report encompasses the company's approach to keeping the patient
journey - from diagnosis and treatment, to on-going disease
management and long-term outcomes - at the centre of how it
prioritises its capabilities and investments.
By creating and
maintaining a dialogue with key stakeholders (patients organizations,
physicians, governments and payers), Sobi seeks to ensure
treatments are delivered in a sustainable way. Sobi refers to
this approach as
Patient and Customer Centric commercialisation. 
About Sobi 
Sobi is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily
focused on inflammation and genetic diseases,
with three late stage biological
development projects within
haemophilia and neonatology. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein
and biologics manufacturing. In 2012, Sobi had total
revenues of SEK 1.9 billion
(EUR 215 M) and about 480 employees. The
share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information
is available at 
Sobi press release April 5, 2013 in pdf version: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE 
For more information - not for publication
Media relations
Oskar Bosson
Head of Communications
T: +46 70 410 71 80 
Investor relations
Jorgen Winroth
Vice President, Head of Investor Relations
T: +1 347 224 0819
Press spacebar to pause and continue. Press esc to stop.